Vertex Pharmaceuticals Inc (VRTX): EBITDA
$4.38B
Year ended 2025-12-31
$5.00B
Trailing 12 months to 2026-06-30
-0.5%
3-year compound annual growth
+8.1%
5-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.38B | n/m | 2026-02-13, From 2025-01-01 |
| 2024-12-31 | -$25.70M | n/m | 2026-02-13, From 2024-01-01 |
| 2023-12-31 | $4.01B | -9.9% | 2026-02-13, From 2023-01-01 |
| 2022-12-31 | $4.46B | +53.2% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $2.91B | -2.0% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $2.97B | +127.4% | 2023-02-10, From 2020-01-01 |
| 2019-12-31 | $1.30B | +84.3% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $707.57M | +283.2% | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | $184.64M | +158.8% | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | $71.33M | n/m | 2019-02-13, From 2016-01-01 |
| 2015-12-31 | -$404.54M | n/m | 2018-02-15, From 2015-01-01 |
| 2014-12-31 | -$629.15M | n/m | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | -$561.64M | n/m | 2016-02-16, From 2013-01-01 |
| 2012-12-31 | $84.92M | -43.0% | 2015-02-13, From 2012-01-01 |
| 2011-12-31 | $148.86M | n/m | 2014-02-11, From 2011-01-01 |
| 2010-12-31 | -$665.62M | n/m | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | -$583.90M | n/m | 2012-02-22, From 2009-01-01 |
| 2008-12-31 | -$430.51M | n/a | 2011-02-17, From 2008-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $4.38B | n/m |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $3.02B | +7.4% |
| Viatris Inc (VTRS) | 2025-12-31 | $135.20M | -95.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.12B | -7.9% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $3.16B | +317.9% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $588.82M | n/m |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | -$388.64M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | -$784.70M | n/m |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $557.24M | n/m |
Compare VRTX, BHC, VTRS, REGN side by side · Screen every company in Pharmaceutical Preparations ↗